Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

References

• Dransfield MT, Bailey W, Crater G, Emmett A, O’Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Primary Care Respir j. 2011;20(1):46–53. doi:10.4104/pcrj.2010.00059
   PubMedGoogle Scholar
• Doyle T, Palmer S, Johnson J, et al. Association of anxiety and depression with pulmonary-specific symptoms in chronic obstructive pulmonary disease. Int J Psychiatry Med. 2013;45(2):189–202. doi:10.2190/PM.45.2.g
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Primary Care Respir j. 2011;20(3):257–268. doi:10.4104/pcrj.2011.00029
   PubMedGoogle Scholar
• Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14(1):112. doi:10.1186/1465-9921-14-112
   PubMedGoogle Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3
   PubMed Web of Science ®Google Scholar
• Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for COPD: a Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. Ann Am Thorac Soc. 2020;17(9):1133–1143. doi:10.1513/AnnalsATS.201912-915OC
   PubMed Web of Science ®Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. doi:10.1136/thoraxjnl-2014-206732
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S130482
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, Cazzola M, Systematic Review A. With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.646
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2019. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed May 21, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed May 21, 2021.
   Google Scholar
• Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing Short-term Deterioration in Maintenance-naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: a Pooled Analysis of Three Randomized Trials. Adv Ther. 2016;33(12):2188–2199. doi:10.1007/s12325-016-0430-6
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003;8(4):504–508. doi:10.1046/j.1440-1843.2003.00501.x
   PubMed Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Donohue JF, et al. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naive Patients With COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2835–2848. doi:10.2147/COPD.S217710
   PubMed Web of Science ®Google Scholar
• Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/COPD.S101612
   PubMed Web of Science ®Google Scholar
• Zheng J, Xu JF, Jenkins M, Assam PN, Wang L, Lipworth BJ. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. Respir Res. 2020;21(1):69. doi:10.1186/s12931-020-1332-3
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
   PubMed Web of Science ®Google Scholar
• Maltais F, Naya I, Vogelmeier CF, et al. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respir Res. 2020;21(1):280. doi:10.1186/s12931-020-01451-8
   PubMed Web of Science ®Google Scholar
• Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1). Int J Chron Obstruct Pulmon Dis. 2016;11:3–12. doi:10.2147/COPD.S85976
   PubMedGoogle Scholar
• Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):143. doi:10.1183/16000617.0113-2016
   Web of Science ®Google Scholar
• Naya I, Tombs L, Lipson DA, Boucot I, Compton C. Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respir Res. 2019;20(1):60. doi:10.1186/s12931-019-1027-9
   PubMedGoogle Scholar
• Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86. doi:10.1186/s12931-017-0566-1
   PubMedGoogle Scholar
• Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS. A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD. Pulm Ther. 2017;3(2):297–316. doi:10.1007/s41030-017-0048-0
   PubMedGoogle Scholar
• Vestbo J, Anderson JA, Calverley PMA, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2010;5:44–49. doi:10.1111/j.1752-699X.2010.00198.x
   Web of Science ®Google Scholar
• Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367–381. doi:10.2147/COPD.S119908
   PubMed Web of Science ®Google Scholar